Moscoso, AlexisKarikari, Thomas KGrothe, Michel JAshton, Nicholas JLantero-Rodriguez, JuanSnellman, AnniinaZetterberg, HenrikBlennow, KajSchöll, Michael2023-05-032023-05-032022-02-28http://hdl.handle.net/10668/20174Clinical trials targeting tau in Alzheimer's disease (AD) need to recruit individuals at risk of tau accumulation. Here, we studied cerebrospinal fluid (CSF) biomarkers and plasma phosphorylated tau (p-tau)181 as predictors of tau accumulation on positron emission tomography (PET) to evaluate implications for trial designs. We included older individuals who had serial tau-PET scans, baseline amyloid beta (Aβ)-PET, and baseline CSF biomarkers (n = 163) or plasma p-tau181 (n = 74). We studied fluid biomarker associations with tau accumulation and estimated trial sample sizes and screening failure reductions by implementing these markers into participant selection for trials. P-tau181 in CSF and plasma predicted tau accumulation (r > 0.36, P  0.36, P  0.37, P  Clinical trials testing tau-targeting therapies may benefit from using fluid biomarkers to recruit individuals at risk of tau aggregation.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/HumansAmyloid beta-PeptidesClinical Trials as TopicAlzheimer Diseasetau ProteinsBiomarkersPositron-Emission Tomographyresearch article35226405open access10.1002/alz.125701552-5279https://doi.org/10.1002/alz.12570